Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURMOUNT-1

Eli Lilly · Phase 3 · Recruiting · Enrollment 2539

NCT07481747

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Arm 1: Tirzepatide 5 mg once weekly + lifestyle interventionn/rn/rn/rn/r
Arm 2: Tirzepatide 10 mg once weekly + lifestyle interventionn/rn/rn/rn/r
Arm 3: Tirzepatide 15 mg once weekly + lifestyle interventionn/rn/rn/rn/r
Arm 4: Placebo once weekly + lifestyle interventionn/rn/rn/rn/r

Not shown

  • Arm 1: Tirzepatide 5 mg once weekly + lifestyle intervention: endpoint not reported
  • Arm 2: Tirzepatide 10 mg once weekly + lifestyle intervention: endpoint not reported
  • Arm 3: Tirzepatide 15 mg once weekly + lifestyle intervention: endpoint not reported
  • Arm 4: Placebo once weekly + lifestyle intervention: endpoint not reported